BiotechTube
Home/Pipeline/Alymsys (bevacizumab-maly)

Alymsys (bevacizumab-maly)

Oncology

ApprovedCommercial

Key Facts

Indication
Oncology
Phase
Approved
Status
Commercial
Company
Amneal Pharmaceuticals

About Amneal Pharmaceuticals

Amneal Pharmaceuticals is a publicly traded, integrated biopharmaceutical company with a 20+ year history focused on expanding access to essential medicines. It operates across three core segments: Complex Generics, Biosciences (biosimilars and injectables), and Specialty branded pharmaceuticals, primarily in CNS and endocrine disorders. The company leverages over 1 million square feet of U.S. manufacturing capacity, has a robust pipeline with 69 pending ANDAs, and is led by its founding Patel brothers, aiming to bring manufacturing of critical medicines back to the United States.

View full company profile

Therapeutic Areas

OncologyNeurology (CNS)GastroenterologyOphthalmologyRespiratoryEndocrine DisordersEmergency/Critical CarePsychiatryHematology

Other Oncology Drugs

DrugCompanyPhase
Mvasi (bevacizumab biosimilar)ViatrisApproved
DRL-17822Dr. Reddy's LaboratoriesPhase 2
Biosimilar PortfolioZydus LifesciencesVarious
therascreen Solid TumorQiagenCommercial
GBR 830Glenmark PharmaceuticalsPhase 1
Bevacizumab BiosimilarGlenmark PharmaceuticalsApproved
Biosimilar (Bevacizumab)Ipca LaboratoriesDevelopment
LockBody Platform AssetsCentessa PharmaceuticalsPre-clinical
EverolimusAmneal PharmaceuticalsApproved
Lenalidomide (Revlimid generic)Amneal PharmaceuticalsApproved
Pemrydi RTUAmneal PharmaceuticalsApproved
FocinezAmneal PharmaceuticalsApproved